Fukuda Denshi (6960) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
12 Nov, 2025Executive summary
Net sales for the six months ended September 30, 2025, were ¥64,807 million, up 0.8% year-over-year.
Operating profit was ¥10,663 million, a 0.1% increase year-over-year; ordinary profit declined 3.0% to ¥10,926 million.
Profit attributable to owners of parent was ¥7,578 million, down 1.7% year-over-year.
Comprehensive income rose 55.3% year-over-year to ¥9,341 million.
Financial highlights
Earnings per share for the period were ¥273.47, up from ¥267.34 a year earlier.
Total assets decreased to ¥212,934 million from ¥221,321 million at the previous fiscal year-end.
Net assets decreased to ¥178,063 million, with a shareholders' equity ratio of 83.6%.
Cash and deposits fell by ¥6,613 million to ¥65,761 million.
Retained earnings increased by ¥4,380 million; treasury shares increased by ¥10,065 million.
Outlook and guidance
Full-year net sales forecast is ¥137,000 million (up 1.4% year-over-year), with operating and ordinary profit both forecast at ¥24,000 million.
Profit attributable to owners of parent is projected at ¥17,000 million (up 8.6%), with EPS of ¥618.05.
No change to the previously announced full-year forecast due to steady sales achievement.
Latest events from Fukuda Denshi
- Slight YoY profit decline offset by strong comprehensive income and stable full-year outlook.6960
Q3 20265 Feb 2026 - Sales rose 4% year-over-year, but profits declined; full-year guidance and dividends unchanged.6960
Q1 20259 Sep 2025 - First-half profits fell on lower sales, but full-year guidance and dividend plans remain unchanged.6960
Q2 20259 Sep 2025 - Profits declined despite stable sales, with mixed segment performance and steady full-year outlook.6960
Q3 20259 Sep 2025 - Slight declines in sales and profit, with FY2026 guidance indicating further contraction.6960
Q4 20259 Sep 2025 - Profits declined despite stable sales; medical treatment and consumables segments showed growth.6960
Q1 20269 Sep 2025